NeoMedica Unveils COPROSS – The New Era of Gut Diagnostics at MEDICA 2025
The NeoMedica Company is set to unveil a major diagnostic innovation at MEDICA 2025 with the introduction of COPROSS – an Integrated Diagnostic Intelligence Platform dedicated entirely to stool testing. This advanced system combines fully automated analysis with intelligent data processing, marking a significant step forward in simplifying and standardizing complex gastrointestinal (GI) diagnostics.
Why COPROSS Matters: An Integrated Approach to GI Diagnosis
Gastrointestinal diseases like IBD (Ulcerative Colitis or Crohn Disease), Enteritis, Diverticulitis, Colorectal Cancer, and IBS often present with similar and overlapping symptoms (e.g., bloating, gas, constipation, diarrhea). Current stool analysis biomarkers, such as Calprotectin, indicate gut inflammation without specifying the location or distinguishing subtypes of conditions like IBS, often leading to unnecessary colonoscopy.
The NeoMedica COPROSS system, as an Integrated Diagnostic Intelligence Platform, addresses these challenges by using an Intelligent choice of product assortment, featuring 25 stool analysis biomarkers. This system is aiming at resolving all possible gastroenterology diagnostic inquiries and functions as a pre-endoscopic filter.
It is about Integrating Diagnostic Intelligence in the sense that it follows the disorders of the gut in the natural sequence: dysbiosis -> epithelial stress -> inflammation -> structural damages.
| Challenge in Traditional Stool Analysis | COPROSS Solution (Integrated Diagnostic Intelligence) |
| Differentiation of Similar Conditions | Comprehensive Marker Panel: COPROSS allows analysis of over 25 different parameters from a single sample extract, aiding in the differential diagnosis of complex digestive disorders (e.g., distinguishing inflammatory IBD from functional IBS – consequently, exclusion of unnecessary colonoscopies, confirmation of Celiac Disease). |
| Diagnostic Complexity & Interpretation | Integrated Diagnostic Intelligence: The platform goes beyond simply running tests by integrating data analysis and potentially offering interpretive suggestions. This is the key innovation. |
| Lack of Standardization & Manual Error | Full Automation and Standardization: COPROSS is a fully-automated monotest immunoanalyzer. Its unique, ready-to-use monotest reagent cartridge system eliminates manual pipetting errors, standardizes sample-to-reagent ratios, and minimizes carry-over, ensuring highly reproducible and reliable results. |
The platform represents a shift from a simple analytical machine to a smart diagnostic partner, incorporating Smart Data Management, Intelligent Validation, and Enhanced Clinical Value.
The GI Orientation Profile: The Pre-Endoscopic Filter
A core feature of the COPROSS system is the Orientation GI (Gastrointestinal Profile), a pattern of five stool biomarkers designed to significantly reduce “wasted” colonoscopies through its function as a Pre-Endoscopic Filter. This profile is based on the principle that Calprotectin never comes first and never comes alone.
After dysbiosis, the epithelium becomes stressed, immediately secreting Zonulin and $\beta$-defensin.
| Biomarker | Diagnostic Role | Clinical Relevance |
| 1. Zonulin (R&D status) | Regulator of tight junctions; indicates increased intestinal permeability or “leaky gut.” | Triggers include Gliadin, gut dysbiosis, infections, stress, and chronic autoimmune activation (Celiac, Crohn’s). |
| 2. beta-defensin (CE marked) | Reflects the innate antimicrobial response and degree of inflammatory reaction at the level of the intestinal epithelium. | Aids in the differential diagnosis of inflammatory and functional GI disorders, and supplements fecal calprotectin measurement. |
| 3. Calprotectin (CE marked) | Highly sensitive marker for differentiation of inflammatory and irritable bowel disease. | Indicates the recruitment of neutrophiles and macrophages. Important in children where invasive procedures are difficult. |
| 4. Lysozyme (R&D status) | Marker of colonic inflammatory activity, complementing Calprotectin. | High and climbing levels suggest inflammation focused in the Colon. Normal Lysozyme levels suggest the Colon is not involved (Small intestine is affected if beta-defensin is low). |
| 5. Fecal Albumin (R&D status) | Helps identify mucosal damage in the lower intestine due to increased permeability and perforations. | A moderate rise means a barrier leakage issue, often seen in UC flares. |
The interpretation of the levels of these five biomarkers allows the physician to differentiate between inflammatory causes and IBS (avoiding colonoscopy in the latter case) and guides doctors to new prescriptions for investigating deeper (e.g., Celiac Diseases, Enteritis, Colorectal cancer, Pancreas issues, and food -non IgE allergies). It is also about confirming the success of Helicobacter pylori eradication therapy.
A Final Word
Dear current and future NeoMedica partners, one more reminder, our stool tests Zonulin, Lysozyme, and Albumin are the Stars of the R&D department and we expect their launch in the very near future; then we will have our complete diagnostic story in real time.
Join us on this extraordinary journey of success as we unveil COPROSS at MEDICA 2025.
